MET 4
Alternative Names: MET-4; MET4-NuBiyota; Microbial ecosystem therapeutics 4Latest Information Update: 31 Jul 2026
At a glance
- Originator NuBiyota
- Class Antineoplastics; Bacteria
- Mechanism of Action Bacteria replacements; Gastrointestinal microbiome modulators
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II/III Solid tumours
- Phase II Squamous cell cancer
Most Recent Events
- 17 Sep 2024 Immunogenicity data from a phase II/III trial in Solid tumours presented at the 49th European Society for Medical Oncology Congress (ESMO-2024)
- 12 May 2023 Phase-II clinical trials in Squamous cell cancer (Late-stage disease, Combination therapy) (PO) (NCT05743777)
- 12 May 2023 Nubiyota terminates a phase II trial in Squamous cell cancer (Late stage disease, Combination therapy) due to financial reasons (NCT05743777)